The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Michael C. Heinrich

Portland VA Medical Center




Name/email consistency: high



  • Portland VA Medical Center, Portland, USA. 2012
  • Division of Hematology/Oncology, Department of Medicine, Portland VA Medical Center and OHSU Knight Cancer Institute, Oregon Health & Science University, USA. 2006 - 2012
  • Department of Hematology and Medical Oncology, Oregon Health & Science University Cancer Institute and Portland VA Medical Center, Portland, Oregon 97239-3098, USA. 2000 - 2008
  • Department of Medicine, Oregon Health & Science University, R&D-19, 3710 SW US Veterans, USA. 2002 - 2006
  • R&D-19 3710 SW US Veterans Hospital Rd, Portland, OR 97207, USA. 2003


  1. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Heinrich, M.C., Griffith, D., McKinley, A., Patterson, J., Presnell, A., Ramachandran, A., Debiec-Rychter, M. Clin. Cancer Res. (2012) [Pubmed]
  2. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Heinrich, M.C., Marino-Enriquez, A., Presnell, A., Donsky, R.S., Griffith, D.J., McKinley, A., Patterson, J., Taguchi, T., Liang, C.W., Fletcher, J.A. Mol. Cancer Ther. (2012) [Pubmed]
  3. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Heinrich, M.C., Joensuu, H., Demetri, G.D., Corless, C.L., Apperley, J., Fletcher, J.A., Soulieres, D., Dirnhofer, S., Harlow, A., Town, A., McKinley, A., Supple, S.G., Seymour, J., Di Scala, L., van Oosterom, A., Herrmann, R., Nikolova, Z., McArthur, A.G. Clin. Cancer Res. (2008) [Pubmed]
  4. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Heinrich, M.C., Maki, R.G., Corless, C.L., Antonescu, C.R., Harlow, A., Griffith, D., Town, A., McKinley, A., Ou, W.B., Fletcher, J.A., Fletcher, C.D., Huang, X., Cohen, D.P., Baum, C.M., Demetri, G.D. J. Clin. Oncol. (2008) [Pubmed]
  5. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. Heinrich, M.C., Owzar, K., Corless, C.L., Hollis, D., Borden, E.C., Fletcher, C.D., Ryan, C.W., von Mehren, M., Blanke, C.D., Rankin, C., Benjamin, R.S., Bramwell, V.H., Demetri, G.D., Bertagnolli, M.M., Fletcher, J.A. J. Clin. Oncol. (2008) [Pubmed]
  6. Does tumor mutational status correlate with clinical response to imatinib? Heinrich, M.C., Corless, C.L. Nat. Clin. Pract. Oncol (2006) [Pubmed]
  7. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). Heinrich, M.C., McArthur, G.A., Demetri, G.D., Joensuu, H., Bono, P., Herrmann, R., Hirte, H., Cresta, S., Koslin, D.B., Corless, C.L., Dirnhofer, S., van Oosterom, A.T., Nikolova, Z., Dimitrijevic, S., Fletcher, J.A. J. Clin. Oncol. (2006) [Pubmed]
  8. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Heinrich, M.C., Corless, C.L., Blanke, C.D., Demetri, G.D., Joensuu, H., Roberts, P.J., Eisenberg, B.L., von Mehren, M., Fletcher, C.D., Sandau, K., McDougall, K., Ou, W.B., Chen, C.J., Fletcher, J.A. J. Clin. Oncol. (2006) [Pubmed]
  9. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. Heinrich, M.C., Corless, C.L. J. Surg. Oncol (2005) [Pubmed]
  10. Targeting FLT3 kinase in acute myelogenous leukemia: progress, perils, and prospects. Heinrich, M.C. Mini. Rev. Med. Chem (2004) [Pubmed]
  11. PDGFRA activating mutations in gastrointestinal stromal tumors. Heinrich, M.C., Corless, C.L., Duensing, A., McGreevey, L., Chen, C.J., Joseph, N., Singer, S., Griffith, D.J., Haley, A., Town, A., Demetri, G.D., Fletcher, C.D., Fletcher, J.A. Science (2003) [Pubmed]
  12. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Heinrich, M.C., Corless, C.L., Demetri, G.D., Blanke, C.D., von Mehren, M., Joensuu, H., McGreevey, L.S., Chen, C.J., Van den Abbeele, A.D., Druker, B.J., Kiese, B., Eisenberg, B., Roberts, P.J., Singer, S., Fletcher, C.D., Silberman, S., Dimitrijevic, S., Fletcher, J.A. J. Clin. Oncol. (2003) [Pubmed]
  13. Is KIT an important therapeutic target in small cell lung cancer?. Heinrich, M.C. Clin. Cancer Res. (2003) [Pubmed]
  14. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. Heinrich, M.C., Blanke, C.D., Druker, B.J., Corless, C.L. J. Clin. Oncol. (2002) [Pubmed]
  15. Posttranscriptional cell cycle-dependent regulation of human FANCC expression. Heinrich, M.C., Silvey, K.V., Stone, S., Zigler, A.J., Griffith, D.J., Montalto, M., Chai, L., Zhi, Y., Hoatlin, M.E. Blood (2000) [Pubmed]
  16. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Heinrich, M.C., Griffith, D.J., Druker, B.J., Wait, C.L., Ott, K.A., Zigler, A.J. Blood (2000) [Pubmed]
WikiGenes - Universities